Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Consensus Rating of “Moderate Buy” from Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.

A number of equities research analysts have issued reports on the company. HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Finally, Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $49.03 on Thursday. The firm’s 50-day moving average price is $48.05 and its 200-day moving average price is $42.49. The company has a current ratio of 0.70, a quick ratio of 0.47 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $17.45 billion, a price-to-earnings ratio of 108.95 and a beta of 0.35. Swedish Orphan Biovitrum has a 12-month low of $28.93 and a 12-month high of $49.03.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. The firm had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. On average, equities research analysts anticipate that Swedish Orphan Biovitrum will post 1.94 EPS for the current fiscal year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.